Mitral Stenosis: Echocardiographic Assessment

Mitral stenosis (MS) is narrowing of the mitral valve orifice that impedes diastolic blood flow from the left atrium to the left ventricle. Echocardiography is the cornerstone of diagnosis, severity assessment, and management planning. This tutorial covers etiology, echocardiographic findings, and severity grading, with thresholds drawn from the 2020 ACC/AHA and 2025 ESC/EACTS valvular heart disease guidelines. For a technique-focused deep dive into each severity measurement — PHT derivation and pitfalls, planimetry technique, PISA, 3D methods, low-gradient severe MS, and exercise hemodynamics — see Mitral Stenosis: Severity Assessment.

Etiology

• Rheumatic heart disease — by far the most common cause of MS worldwide, and the dominant cause of MS-related death globally. Prevalence has declined in high- and middle-income countries but remains a major problem in lower-income regions, where it particularly affects young patients — often presenting in the teens through the 30s where disease prevalence is high, versus an older presentation (ages 50–70) decades after the initial rheumatic episode in lower-prevalence regions.
• Degenerative MS related to mitral annular calcification (MAC) — a distinct, age-dependent pathology seen with increasing frequency in elderly patients in high-income countries, requiring a different treatment approach than rheumatic MS.
• Rare causes — congenital mitral valve anomalies (e.g., parachute mitral valve), severe MAC extending into the leaflets, and left atrial myxoma obstructing the valve orifice — functional obstruction from a myxoma is itself assessed by the same pressure half-time method used for true rheumatic MS.

Clinical Relevance

Mitral stenosis commonly leads to left atrial enlargement, pulmonary hypertension, reduced cardiac output with associated exertional symptoms, and — particularly in the presence of atrial fibrillation — a meaningful risk of left atrial thrombus and systemic embolism. Echocardiography plays a central role in evaluating each of these downstream consequences, not just the valve itself.

M-Mode Findings

• Thickened mitral valve leaflets — a characteristic rheumatic change
• Reduced E-F slope, typically < 30 mm/sec, indicating impaired early diastolic valve opening
• Paradoxical anterior motion of the posterior mitral leaflet during diastole, from restricted mobility of the fused leaflets
• A decreased A-wave, reflecting elevated left atrial pressure
• Left atrial enlargement, a sign of chronic pressure overload

2D Echocardiographic Findings

• Thickened mitral valve leaflets and chordae
• Diastolic doming of the anterior mitral leaflet — the classic “hockey stick” appearance of rheumatic MS, shown schematically below
• Left atrial enlargement, which may contain thrombus (particularly with atrial fibrillation) — look carefully, especially in the left atrial appendage
• Right ventricular and right atrial enlargement in advanced cases, reflecting pulmonary hypertension
• Direct planimetry of the valve orifice in the parasternal short-axis view is the most accurate method for determining anatomic mitral valve area, since — unlike Doppler-derived methods — it doesn’t depend on hemodynamic assumptions
• Assess leaflet and subvalvular morphology for suitability for percutaneous balloon mitral commissurotomy (PMC) using the Wilkins score (below)
• Check for associated abnormalities: a coexisting atrial septal defect (Lutembacher syndrome), and other valve lesions such as concomitant aortic or tricuspid stenosis

Doppler Assessment

Pulsed-wave and continuous-wave Doppler:

• Turbulent flow across the mitral valve during diastole
• An increased peak mitral E velocity (> 1.3 m/s) is a qualitative sign of obstruction, though it is supportive rather than a primary grading parameter on its own
• Pressure half-time (PHT) — the time for the peak diastolic transmitral gradient to fall by half — is the most widely used Doppler method to estimate MVA in a native valve. This same PHT-based formula is specifically discouraged for a prosthetic mitral valve, where it frequently overestimates EOA — the continuity equation is preferred there instead:

MVA (cm²) = 220 / PHT (ms)

A longer PHT indicates more severe stenosis, since a smaller orifice takes longer to equalize left atrial and LV pressure. PHT has real limitations: it depends on LV and LA compliance in addition to stenosis severity, and can be misleading immediately after PMC or in the presence of significant AR.

• Mean pressure gradient (MPG) further characterizes hemodynamic severity, though because it varies with heart rate and forward flow, it is not part of the formal staging criteria in the current ACC/AHA guideline — it is still routinely reported, and is typically 5–10 mmHg in severe MS at a normal heart rate.
• Pulmonary pressures — systolic pulmonary artery pressure (SPAP/PASP) should be measured to assess for pulmonary hypertension. An elevated PASP (> 50 mmHg) is one of the hemodynamic consequences that supports a diagnosis of severe MS.

Color flow Doppler:

• A flame-shaped, turbulent diastolic jet at the mitral orifice extending into the LV
• Also used to assess for coexisting mitral regurgitation or other valvular abnormalities

Guideline-Based Severity Grading

This is the single most important distinction to know: current guideline-defined “severe” MS uses a substantially different threshold than the classic three-tier echocardiographic grading scheme many labs and textbooks still use for descriptive reporting.

Current guideline staging (ACC/AHA 2020 Table 16; ESC 2025 uses an equivalent threshold):

Stage	MVA	PHT	Hemodynamic consequences
Progressive MS	> 1.5 cm²	< 150 ms	Mild–moderate LA enlargement, normal resting pulmonary pressure
Clinically severe MS	≤ 1.5 cm²	≥ 150 ms	Severe LA enlargement, PASP > 50 mmHg

An MVA ≤1.5 cm², together with supporting clinical factors (symptoms, high thromboembolic risk, or hemodynamic decompensation), is what both the ACC/AHA and ESC/EACTS guidelines use to define clinically severe MS — this drives the timing of intervention.

Classic (descriptive) echocardiographic grading, still widely used in report templates:

Severity	MVA	PHT	Mean gradient
Mild	1.5–2.5 cm²	90–150 ms	< 5 mmHg
Moderate	1.0–1.5 cm²	150–219 ms	6–12 mmHg
Severe	< 1.0 cm²	> 220 ms	> 12 mmHg

Neither scheme is “wrong” — they answer slightly different questions. The classic scheme descriptively grades stenosis across a continuum; the current guideline staging identifies the specific threshold (MVA ≤1.5 cm²) at which intervention starts to meaningfully change outcomes, which is a lower MVA-based bar for “severe” than the classic scheme’s < 1.0 cm² cutoff would suggest. When reporting severity for clinical decision-making, favor the guideline threshold; the classic tiers remain useful for describing mild-to-moderate disease on a continuum.

A low-gradient severe MS pattern — MVA < 1.5 cm² with a mean gradient < 10 mmHg — is recognized by the 2025 ESC/EACTS guideline as a challenging pattern to manage, often seen in older patients with less favorable valve anatomy.

Advanced Techniques

• 3D echocardiography provides more precise measurement of mitral valve area and leaflet morphology than 2D planimetry alone — see Three-Dimensional Echocardiography for how 3D-guided planimetry is performed.
• Contrast echocardiography is useful for identifying left atrial thrombus, particularly when imaging conditions are suboptimal.
• Transesophageal echocardiography (TEE) is the gold standard for detecting left atrial thrombus and for detailed assessment of mitral valve morphology, and is essential before PMC — see Transesophageal Echocardiography for the specific views used to interrogate the left atrial appendage and mitral valve.

The Wilkins Score

The Wilkins score assesses valve and subvalvular morphology to help predict suitability for PMC. Four features are each graded 1 (best) to 4 (worst), for a total score of 4–16:

1. Mobility — from a highly mobile valve with only the leaflet tips restricted (1) to little or no forward leaflet movement in diastole (4)
2. Leaflet thickening — from near-normal thickness of 4–5 mm (1) to severe thickening of all leaflet tissue exceeding 8 mm (4)
3. Subvalvular thickening — from minimal thickening just below the leaflets (1) to extensive thickening and shortening reaching the papillary muscles (4)
4. Calcification — from a single area of increased echo brightness (1) to extensive brightness throughout most of the leaflet tissue (4)

A total score >8 suggests a less favorable candidate for balloon valvotomy; lower scores predict a better procedural and long-term result from PMC.

Clinical Applications of Echocardiography in MS

• Diagnosis — confirming MS and grading its severity
• Pre-intervention evaluation — assessing valve morphology (Wilkins score) for PMC suitability, and excluding left atrial thrombus and significant concomitant mitral regurgitation, both of which can preclude PMC
• Post-treatment follow-up — evaluating valve function after PMC or surgery and detecting complications such as restenosis or new regurgitation

Practical Pearls

• Remember the guideline-versus-classic-grading distinction above — it’s the detail most likely to cause confusion when comparing an echo report to a guideline recommendation.
• Planimetry and PHT can disagree; when they do, consider which assumptions might be violated (poor image quality for planimetry; abnormal LA/LV compliance, significant AR, or a recent PMC for PHT).
• Always look for left atrial thrombus and assess for concomitant MR before a patient is referred for PMC — either can change the management plan entirely.
• A coexisting atrial septal defect with MS (Lutembacher syndrome) can mask the severity of MS hemodynamically by decompressing the left atrium — worth considering when the clinical and echocardiographic pictures don’t quite match.
• In apparently asymptomatic patients with significant MS, exercise-induced pulmonary hypertension independently predicts mortality — see Stress Echocardiography for how this finding factors into timing intervention.